Kisunla
FDA Approves Updated Dosing for Lilly’s Kisunla to Lower Brain Swelling Risk
FDA; Kisunla; Eli Lilly; Alzheimer’s disease; dosing regimen; brain swelling; ARIA; safety; label update; TRAILBLAZER-ALZ 6
CHMP Recommends Five New Drugs and Reviews Eli Lilly’s Kisunla
CHMP; EMA; new drug approvals; Eli Lilly; Kisunla; biosimilars; hyperphosphatemia; myopia; March 2025; regulatory review
Leqembi wins EU authorization for some Alzheimer’s patients, giving Biogen, Eisai a boost over Lilly
Leqembi, EU, Eisai, Eli Lilly, ARIA, Biogen, authorization, Alzheimer, Kisunla, Restricted, Apolipoprotein E4, High
Alzheimer’s Market Set for Eightfold Boom: Lilly, Eisai, and Biogen Lead the Charge
Alzheimer’s disease market, Eli Lilly, Eisai, Biogen, Market growth, Donanemab (Kisunla), Leqembi
Eli Lilly’s Kisunla Shows Reduced Brain Swelling with Modified Dosing Regimen in Alzheimer’s Patients
Eli Lilly, Kisunla, Alzheimer’s disease, brain swelling, modified dosing regimen, ARIA-E risk reduction
Modified Dosing Regimen of Eli Lilly’s Alzheimer’s Drug Kisunla (Donanemab) Reduces Brain Swelling
Alzheimer’s disease, Eli Lilly, Kisunla (donanemab), Modified dosing regimen, ARIA-E (amyloid-related imaging abnormalities with oedema/effusion), Brain swelling, TRAILBLAZER-ALZ 6 Phase IIIb trial
NICE Rejects Alzheimer’s Drug Kisunla Despite UK Regulatory Approval
NICE, Alzheimer’s disease, donanemab, Kisunla, Eli Lilly, MHRA, NHS, cost-effectiveness
FDA Approves Eli Lilly’s Alzheimer’s Drug Donanemab, Offering New Treatment Option
Alzheimer’s disease, Eli Lilly, FDA approval, donanemab, Kisunla, anti-amyloid monoclonal antibody, cognitive decline, amyloid plaques, treatment options